



Par Pharmaceutical  
300 Tice Blvd, Suite 230  
Woodcliff Lake, NJ 07677

www.parpharm.com

March 27, 2023

[AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov)

Notice of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

Dear Office of the Vermont Attorney General,

Par Pharmaceutical, Inc. ("Par") is issuing this notice pursuant to 18 V.S.A. § 4637(b), which asks prescription drug manufacturers to provide the Office of the Attorney General (the "Office") written notice within three calendar days of releasing a drug in the commercial market whose wholesale acquisition cost ("WAC") exceeds the threshold set for a specialty drug under the Medicare Part D Program.

On March 23, 2023, Par informed potential customers the following drug product was available for order:

<b>NDC #</b>	<b>Product Description</b>
49884-0158-02	Everolimus Tablets 0.25mg 60s
49884-0159-02	Everolimus Tablets 0.5mg 60s

On or about March 27, 2023, Par intends to commence shipping the aforementioned drug product to its third-party customers.

The WAC for the drug product identified above exceeds the threshold set for a specialty drug under the Medicare Part D Program. Please note that the WAC-related information provided in this notice may be subject to change.

In the event Vermont S. 92 and the laws it implements, including 18 V.S.A. § 4637, are found invalid, Par reserves all of its legal rights. In issuing this notice in an attempt to comply with 18 V.S.A. § 4637, Par does not waive any legal claims or legal rights related to potential constitutional defects with Vermont S. 92.

Sincerely,

Scott Sims, SVP & GM Injectable Solutions and Generics  
Par Pharmaceutical an endo company